GlassScriptPhysician profile
Nicholas Stroumbakis
NPI 1871597641
$1,073.09
in general payments reported to CMS, 2019-2025
14 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2022: $153 · 2023: $43.73 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $298.44 | 2022-2025 | General - Kidney Stone Disease, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $296.78 | 2019 | |
| Antares Pharma, INC. | $85.99 | 2019 | |
| Pfizer INC. | $73.72 | 2019 | |
| Endo Pharmaceuticals INC. | $55.35 | 2019 | |
| Coloplast Corp | $46.28 | 2019 | |
| Therapeuticsmd, INC. | $38.70 | 2019 | |
| Janssen Biotech, INC. | $38.32 | 2019 | |
| Neotract INC. | $35.74 | 2019 | |
| Intuitive Surgical, INC. | $35.26 | 2019 | |
| Allergan, INC. | $18.81 | 2019 | |
| 180 Medical, INC. | $18.19 | 2019 | |
| Zyla Life Sciences, INC. | $17.38 | 2019 | |
| Mission Pharmacal Company | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Stroumbakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.